Dr. Hark K. Kim’s lab focuses on discovery of cancer genes, diagnostic/predictive biomarkers and therapeutic targets. For these purposes, he is leading comprehensive genomic and proteomic analyses on tumor tissue samples with clinical annotation. Recently, Dr. Kim’s lab has developed the first genetically-engineered mouse models and cell line models for metastatic gastric cancer. Using these preclinical models, he strives to identify novel biomarkers, and molecular mechanisms of putative cancer genes and chemotherapy resistance. Ongoing efforts are being made to develop various genetically-engineered mouse models for gastric cancer that recapitulate human diffuse type gastric cancers. His team also runs a pharmacokinetics/pharmacodynamics and bioanalysis lab to support early phase clinical trials and proteogenomics-guided targeted therapy trials.